|
|
|
| Analysis of Changes of Plasma Lipoprotein a and Related Apolipoproteins in Patients with Coronary Heart Disease |
| LI Zhao-qi, WANG Dong, XIAO Shao-wu |
| Department of Cardiology, the Wenchang Hospital, Wenchang, Hainan Province, 571300 |
|
|
|
|
Abstract 【Objective】To investigate the changes and clinical significance of lipoprotein a [Lp (A)] and ApoA-1,ApoB in patients with coronary heart disease. 【Methods】 Sixty-five patients with coronary heart disease treated in our hospital from January 2016 to April 2017 were retrospectively analyzed. Data (observation group), while 65 healthy volunteers who were examined in our hospital at the same time were classified as control group. The clinical data and laboratory results of all subjects were collected from the inpatient electronic medical record system to collect age, sex, whether or not they were suffering from chronic diseases such as hypertension, diabetes and hyperlipidemia. The plasma levels of Lp(A), ApoA-1, ApoB and ApoB/ApoA-1 were compared between the two groups. The predictive value of the above laboratory indexes for coronary heart disease (CHD) was evaluated by the (ROC) curve of the operating characteristics of the subjects. 【Results】The serum Lp (A), ApoB, ApoB/ ApoA-1 level in the observation group was significantly higher than that in the control group ( P < 0.05), and the serum ApoA-1 level in the observation group was lower than that in the control group, but the difference was not statistically significant ( P > 0.05). The evaluation of ROC curve showed that ApoB/ApoA-1 was the most effective in the diagnosis of coronary heart disease. The AUC (95%CI) of ROC curve was 0.81(0.74~0.89)and 0.78(0.70~0.86). The optimal diagnostic critical value value of Lp(A),ApoB, ApoB/ApoA-1 was 156.4 mg/L, 0.83 g/L ,1.15. Logistic regression analysis showed that Lp(A)> 156.4 mg/L, ApoB> 0.83 g/L, ApoB/ApoA-1> 1.15 were independent risk factors of coronary heart disease.【Conclusions】The high level of Lp(A), ApoB, ApoB/ApoA-1 in patients with coronary heart disease (CHD) is a potential clinical marker for the diagnosis of CHD. Lp(A)> 0.83 g/L and ApoB/ApoA-1> 1.15 are independent risk factors for coronary heart disease.
|
|
Received: 29 May 2018
|
|
|
|
|
|
[1] 张彩华,王开蓉. 脂蛋白(a)载脂蛋白与超敏C反应蛋白联合检测在冠心病诊断中的意义[J].检验医学与临床,2013,10(22):3034-3035.
[2] 李伟聪,何昆仑,武强. 冠心病合并代谢综合征患者的脂质和载脂蛋白水平分析[J].解放军医学院学报,2013,34(6):570-572.
[3] 叶任高. 内科学[M].5版,北京,人民卫生出版社,2002:310.
[4] 黄卓山,钟钧琳,罗艳婷,等. 冠心病患者LDL-C/HDL-C比值与冠脉病变严重程度的相关性[J].中山大学学报(医学版),2018,39(2):303-308.
[5] 褚杰. 载脂蛋白及凝血指标与冠心病患者冠脉病变程度的关系[J].2017,39(2):190-192.
[6] 颜丽,何津春,王志禄,等. 载脂蛋白与家族性高胆固醇血症家系成员冠心病患病关系的研究[J].兰州大学学报(医学版),2016,42(5):31-35.
[7] 童明宏,陶荣霞,李盈,等. 载脂蛋白E及脂蛋白(a)与冠心病的相关性分析[J].检验医学,2017,32(6):490-494.
[8] Laschkolnig A, Kollerits B, Lamina C,et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts[J]. Cardiovasc Res,2014,103(1):28-36. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(7): 1360-1363. |
|
|
|
|
2018, Vol. 35 
